Published by Josh White on 7th November 2025
(Sharecast News) - Scancell Holdings reported strong phase two results for its Immunobody iSCIB1+ cancer immunotherapy on Friday, showing significant improvements in progression-free survival for patients with late-stage melanoma.
URL: http://www.digitallook.com/dl/news/story/35480773/...